United Therapeutics (NASDAQ:UTHR) Stock Rated “Buy” in New Coverage at HC Wainwright

Posted by Brenda Bartman on Nov 9th, 2026

Investment analysts at HC Wainwright began coverage on shares of United Therapeutics (NASDAQ:UTHR – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set a “buy” rating and a $660.00 price target on the biotechnology company’s stock. HC Wainwright‘s target price would suggest a potential upside of 17.43% from the stock’s current price.

Several other equities analysts also recently issued reports on UTHR. Leerink Partners upped their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $728.00 target price on shares of United Therapeutics in a research note on Wednesday, October 14th. Weiss Ratings downgraded United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. TD Cowen boosted their price target on United Therapeutics from $675.00 to $700.00 and gave the company a “buy” rating in a report on Thursday. Finally, BTIG Research increased their price target on United Therapeutics from $728.00 to $768.00 and gave the stock a “buy” rating in a research note on Wednesday, November 4th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $676.40.

Read Our Latest Stock Analysis on United Therapeutics

United Therapeutics Stock Performance

NASDAQ:UTHR opened at $562.02 on Monday. The firm has a market cap of $23.94 billion, a price-to-earnings ratio of 21.21, a price-to-earnings-growth ratio of 3.78 and a beta of 0.49. The company’s 50-day moving average is $533.99 and its two-hundred day moving average is $533.42. United Therapeutics has a 12-month low of $444.04 and a 12-month high of $614.23.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The biotechnology company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.01 by ($0.30). The firm had revenue of $832.50 million for the quarter, compared to analyst estimates of $781.14 million. United Therapeutics had a return on equity of 19.18% and a net margin of 38.61%. United Therapeutics’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the prior year, the business earned $7.16 earnings per share. On average, equities research analysts forecast that United Therapeutics will post 24.77 earnings per share for the current fiscal year.

United Therapeutics announced that its Board of Directors has initiated a share repurchase program on Thursday, October 22nd that allows the company to buy back $2 billion in shares. This repurchase authorization allows the biotechnology company to buy up to 8.3% of its stock through open market purchases. Share repurchase programs are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity

In other news, EVP Paul A. Mahon sold 8,300 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $598.67, for a total transaction of $4,968,961.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $27,043,121.24. This represents a 15.52% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 1,960 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $597.76, for a total transaction of $1,171,609.60. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $193,939,047.68. This represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 401,528 shares of company stock valued at $213,440,124 in the last 90 days. 8.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. BlackRock Inc. purchased a new stake in shares of United Therapeutics during the 2nd quarter valued at $2,868,735,000. Janus Henderson Group PLC increased its holdings in shares of United Therapeutics by 8.9% during the 1st quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company’s stock worth $514,016,000 after buying an additional 70,829 shares during the last quarter. Jupiter Topco LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter worth $450,140,000. Bank of New York Mellon Corp purchased a new position in shares of United Therapeutics in the 2nd quarter worth $159,522,000. Finally, Caisse de depot et placement du Quebec purchased a new position in shares of United Therapeutics in the 2nd quarter worth $154,304,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma.

Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs.